What’s Going On With Teladoc Health Stock Today?

Teladoc Health, Inc. (NYSE: TDOC) shares are trading lower on Thursday.

Teladoc Health, Inc. (NYSE:TDOC) shares are trading lower on Thursday. The stock has continued to trend lower following the release of the company’s third-quarter earnings on Tuesday.
 

What To Know: Teladoc reported quarterly losses of 35 cents per share, which beat the analyst consensus estimate of 37 cents, and quarterly sales of $660.24 million which missed the analyst consensus estimate of $664.11 million.

The company also issued guidance, with fourth-quarter revenue anticipated to be between $658 million and $683 million, versus the $686.56 million estimate.

Full-year 2023 revenue is estimated to be between $2.6 billion and $2.625 billion, versus the $2.63 billion estimate.

News of the mixed results and guidance below estimates caused shares to trade lower Wednesday and into Thursday.

Additionally, on Wednesday, two analysts lowered their price targets on the stock. Oppenheimer analyst Michael Wiederhorn maintained Teladoc Health with a Outperform and lowered the price target from $35 to $26 and RBC Capital analyst Sean Dodge maintained the stock with a Outperform and lowered the price target from $35 to $30.

It is worth noting that Teledoc stock has hit a new 52-week low.

Related Link: These Quality Stocks Are Becoming A Deal For Long-Term Investors

TDOC Price Action: Shares of TDOC were down 7.12% at $16.17 at the time of publication, according to Benzinga Pro.

Image by Tumisu from Pixabay

Total
0
Shares
Related Posts
Read More

What’s Going On With Candel Therapeutics Stock?

Candel Therapeutics, Inc. (NASDAQ:CADL) shares are trading higher Thursday after the company received FDA orphan drug designation for CAN-2409 for the treatment of pancreatic cancer. "We recently reported data from the phase 2 randomized clinical trial of CAN-2409 in borderline resectable pancreatic cancer, showing that CAN-2409, when added to standard of care, more than doubled the median overall survival obtained with standard of care alone," said Paul Peter Tak, MD, PhD, CEO of Candel.

CADL